Press Releases PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
312.5 ^TWD	+0.64%		+4.34%	-9.68%

26/04	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI
24/04	PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	02/04	AQ
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft	02/11	BU
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate	03/23/03	BU
PharmaEssentia Included in FTSE Russell Indices	18/23/18	BU
PHARMAESSENTIA AND MPN ADVOCACY AND EDUCATION INTERNATIONAL LAUNCH NEW EDUCATIONAL INITIATIVE TO EMPOWER PEOPLE LIVING WITH POLYCYTHEMIA VERA	15/23/15	AQ
New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera	04/23/04	BU
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera	30/23/30	BU
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America	02/23/02	BU
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera	23/23/23	BU
PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)	03/23/03	BU
PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development	21/23/21	BU
PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America	23/23/23	BU
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera	02/23/02	BU
PharmaEssentia Establishes a New Research and Development Facility in the Boston Area	04/23/04	BU
PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference	03/23/03	BU
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey	12/22/12	BU
Pharmaessentia to Host Investor Day in New York City on November 30, 2022	21/22/21	BU
Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera	03/22/03	BU
PharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy	20/22/20	BU
Hepatitis C Virus Infection Pipeline Landscape Analysis of 20+ Companies by DelveInsight	12/22/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PharmaEssentia Corporation

Equities

6446

TW0006446008

Press Releases

Filters